Glaxo Wellcome
Article Abstract:
Glaxo Wellcome and SmithKline Beechams are likely to merge their research and development activities, a deal that needs the approval of stockholders. Salomon Smith Barney and Nomura give neutral ratings for the company's stocks, and Charterhouse Securities rates them a buy.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Glaxo Wellcome
Article Abstract:
Glaxo Wellcome sought to achieve a merger with SmithKline Beecham, but the attempt has failed. Glaxo Wellcome has been affected by the end of the patent for its anti-ulcer preparation, Zantac, and by the strength of pound sterling, and the company's sales and pre-tax profit have dropped, according to preliminary results for 1997. Zantac has been the company's best-selling product. Glaxo's Aids drugs have not increased sales as much as expected. Judging by the results, Glaxo's interest in a merger could be defensive.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Glaxo Wellcome
Article Abstract:
Glaxo Wellcome has issued a profit warning that growth will not be as much as forecast, but the company is in a strong long-term position due to a number of factors such as an ageing population. The company's stock price could still be affected by short-term setbacks, and institutional investors often give weight to short-term performance. There are a number of product launches, and the company has a broad drugs portfolio, focusing on central nervous system, viral and respiratory treatments.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1999
User Contributions:
Comment about this article or add new information about this topic: